Novo Nordisk cuts Ozempic, Wegovy prices

COPENHAGEN, Feb. 24 – Novo Nordisk said it will cut U.S. list prices for its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic effective Jan. 1, 2027, lowering the monthly list price to $675, a Reuters report said.

The company said the changes amount to roughly a 50% cut for Wegovy and a 35% cut for Ozempic and apply to all doses, with the same $675 list price also set for Rybelsus and a new Wegovy pill, according to Novo’s press release.

Shift toward insured patients

Novo said the lower list prices are aimed at patients whose out-of-pocket costs are tied to list prices, such as those in high-deductible plans or with coinsurance, CNBC reported.

The company said the list-price changes do not affect its direct-to-patient self-pay prices or ongoing access programs, according to the company announcement and confirmed in a Reuters summary.

Competitive pressure in the GLP-1 market

High demand for GLP-1 weight-loss drugs has intensified competition between Novo Nordisk and rival Eli Lilly, with growing use of cash-pay channels pushing companies to adjust pricing, Reuters said.

CNBC noted that Lilly has taken a larger share of the GLP-1 market in recent months, which Novo hopes to counter by easing affordability for insured patients, according to its report.

Medicare timing and policy backdrop

NBC News said the Jan. 1, 2027 effective date aligns with lower prices set under federal Medicare negotiations for older adults, underscoring the policy pressure around high list prices, NBC News reported.

Novo framed the move as a way to broaden access for people with obesity and type 2 diabetes while keeping its other access programs intact, the company said in its release.

How we report: We select the day’s most important stories, confirm facts across multiple reputable sources, and avoid anonymous sourcing. Our goal is clear, balanced coverage you can trust–because transparency and verification matter for informed readers.